Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
基本信息
- 批准号:10601077
- 负责人:
- 金额:$ 22.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-15 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAdoptedAllogenicAnimalsAntibody-drug conjugatesAutologousAutologous TransplantationBLT miceBerlinCCR5 geneCell TransplantationCellsChimerismChronicClinical TrialsCollaborationsComplicationDevelopmentDiseaseDonor personDoseEngineeringEngraftmentEnvironmentFrequenciesGene ModifiedGenerationsGenesGenetic RecombinationGoalsHIVHIV InfectionsHIV/AIDSHematopoieticHematopoietic Stem Cell TransplantationHematopoietic SystemHematopoietic stem cellsHospitalizationImmuneImmune systemImmunityImmunologic Deficiency SyndromesInfectionInstitutionInterventionLeadLifeLondonMacaca mulattaMalignant NeoplasmsMarrowMethodsModelingMorbidity - disease rateNon-MalignantPTPRC genePatientsPopulationProcessPropertyProto-Oncogene Protein c-kitReagentRegimenResistanceResourcesRhesusScheduleStem cell transplantT-LymphocyteTechnologyToxic effectTransplantationViralViral reservoirVirusWithdrawalWorkantiretroviral therapycell regenerationcellular developmentchemokine receptorchimeric antigen receptorclinical applicationconditioningdelta receptorsdisorder controlengineered stem cellsexperiencegraft vs host diseaseimmune reconstitutionimprovedneutralizing antibodynovelpreclinical developmentpreservationsimian human immunodeficiency virusstem cell engraftmentstem cellssuccesstrial planning
项目摘要
Abstract
The cure of HIV using hematopoietic stem cell (HSC) transplant is supported from the
experience of the `Berlin patient'. Recent results from patients in London and Düsseldorf are very
encouraging and potentially bolster transplant as a cure for HIV. What remains a challenge is to
reduce the complexity of hematopoietic stem cell transplant so that it may be more readily adopted
in settings that are not acutely life threatening such as chronic HIV disease. Gene editing will
make autologous cell transplant possible thereby eliminating the devastating complication of graft
versus host disease and address limited availability of allogeneic CCR5 ∆32/∆32 donors. However,
`conditioning' to enable stem cells to engraft the marrow is highly toxic and requires resource
intensive hospitalization as currently practiced.
We aim to develop nongenotoxic conditioning (NGC) that leverages antibody drug conjugates
(ADCs) to specifically target and deplete hematopoietic cell populations as a niche sparing
method with reduced toxicity. By investigating ADCs that are HSPC-specific (anti-CD117
targeting) or more broadly immune depleting (anti-CD45 targeting), we aim to identify the optimal
NGC strategy for enabling efficient HSC transplant in immunodeficiencies. We will combine our
ADC-based conditioning with autologous gene-modified cell transplants in animal infection
models to identify a lead strategy with translational value. The specific aims of this project are:
Specific aim 1. Optimize the dose and schedule of treating NHP with anti-CD117 ADC to achieve
durable donor chimerism.
Specific aim 2. Optimize the dose and schedule of treating NHP with anti-CD45 ADC to achieve
durable donor chimerism.
Specific aim 3. Determine whether nongenotoxic conditioning and gene-modified HSC
transplant enable disease control in infected animals.
If successful, this project will provide specific interventions that can lower the barrier for gene
modified HSC transplantation as an approach to cure HIV/AIDS.
摘要
使用造血干细胞(HSC)移植治愈艾滋病毒得到了来自
《柏林病人》的经历。伦敦和杜塞尔多夫的患者最近的结果非常好
鼓励并有可能支持将移植作为治疗艾滋病毒的方法。仍然存在的挑战是
降低造血干细胞移植的复杂性,以便更容易采用
在不是严重威胁生命的环境中,例如慢性艾滋病毒疾病。基因编辑将
使自体细胞移植成为可能,从而消除移植的破坏性并发症
针对宿主疾病,并解决同种异体CCR5∆32/∆32捐赠者的有限可获得性。然而,
使干细胞能够植入骨髓的“条件调节”是剧毒的,需要资源。
按照目前的做法进行重症住院治疗。
我们的目标是开发利用抗体药物结合物的非遗传毒性调节(NGC)。
(ADC)专门针对和消耗造血细胞群体,作为一种利基节约
方法降低毒性。通过调查HSPC特异性的ADC(抗CD117
靶向)或更广泛的免疫消耗(抗CD45靶向),我们的目标是确定最佳的
使免疫缺陷患者进行高效的造血干细胞移植的NGC策略。我们将把我们的
自体基因修饰细胞移植在动物感染中基于ADC的调节作用
确定具有转换价值的领先战略的模型。该项目的具体目标是:
具体目的1.优化抗CD117 ADC治疗NHP的剂量和方案,以实现
持久的供体嵌合体。
具体目标2.优化抗CD45 ADC治疗NHP的剂量和方案,以实现
持久的供体嵌合体。
具体目标3.确定非遗传毒性调节和基因修饰的HSC
移植使受感染的动物能够控制疾病。
如果成功,这个项目将提供可以降低基因障碍的具体干预措施。
改良的造血干细胞移植作为治疗艾滋病毒/艾滋病的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Glen D Raffel其他文献
Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)
- DOI:
10.1182/blood-2023-190037 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
John DiPersio;Brenda W Cooper;Hyung C Suh;Divya Koura;Lea Bernard;Nirali N. Shah;Roland B. Walter;Miguel-Angel Perales;Markus Mapara;Roni Tamari;Michael R. Loken;Kyle Breitschwerdt;Sritama Nath;Glen D Raffel;Guenther Koehne - 通讯作者:
Guenther Koehne
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
- DOI:
10.1182/blood-2024-205641 - 发表时间:
2024-11-05 - 期刊:
- 影响因子:
- 作者:
John F. DiPersio;Guenther Koehne;Nirali N. Shah;Lea Bernard;Hyung C Suh;Divya Koura;Miguel Angel Perales;Roni Tamari;Muhammad Umair Mushtaq;Joseph E. Maakaron;Michael R. Loken;Darren A Stanizzi;Melissa M. Lee-Sundlov;Sanjana Thosar;Sharon L Hyzy;Glen D Raffel;Brenda W Cooper - 通讯作者:
Brenda W Cooper
Glen D Raffel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Glen D Raffel', 18)}}的其他基金
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
10163910 - 财政年份:2020
- 资助金额:
$ 22.33万 - 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
10409804 - 财政年份:2020
- 资助金额:
$ 22.33万 - 项目类别:
Hematopoietic regulation through Ott1-dependent alternative splicing
通过 Ott1 依赖的选择性剪接进行造血调节
- 批准号:
8708200 - 财政年份:2013
- 资助金额:
$ 22.33万 - 项目类别:
Hematopoietic regulation through Ott1-dependent alternative splicing
通过 Ott1 依赖的选择性剪接进行造血调节
- 批准号:
8579535 - 财政年份:2013
- 资助金额:
$ 22.33万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
7336370 - 财政年份:2005
- 资助金额:
$ 22.33万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
7176783 - 财政年份:2005
- 资助金额:
$ 22.33万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia.
婴儿急性巨核细胞白血病小鼠模型。
- 批准号:
7008162 - 财政年份:2005
- 资助金额:
$ 22.33万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
6851221 - 财政年份:2005
- 资助金额:
$ 22.33万 - 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
- 批准号:
7563228 - 财政年份:2005
- 资助金额:
$ 22.33万 - 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
- 批准号:
9891829 - 财政年份:
- 资助金额:
$ 22.33万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 22.33万 - 项目类别:
Research Grant